We developed a risk stratification prognostic signature based on CD8 T cells, which accurately predicts the prognosis of HCC patients' outcomes and serves as a crucial reference for clinical treatment decision-making and drug selection. This evidence concerns the gene CD8A and hepatocellular carcinoma.